Table 3.
Summary of clinical utilities as a predictive biomarker of treatment.
| Drug | Manufacture | Target | Diseases | Specimens | Outcomes of Periostin As Predictive or Monitoring Biomarker |
|---|---|---|---|---|---|
| Lebrikizumab | Genentech | IL-13 | Asthma | Serum | Patients with high pretreatment levels of serum periostin had greater improvement in lung function with lebrikizumab than did patients with low periostin levels [20]. |
| Serum | Lebrikizumab-treated subjects with elevated baseline levels of peripheral blood eosinophils, serum IgE, or periostin exhibited a greater reduction in late asthmatic response [171]. | ||||
| Serum | Treatment with lebrikizumab reduced the rate of asthma exacerbations, which was more pronounced in the periostin-high patients (60% reduction) than in the periostin-low patients (5% reduction) [59]. | ||||
| Serum | Lung function also improved the following: lebrikizumab treatment, with greatest increase in FEV1 in periostin-high patients [58]. | ||||
| Omalizumab | Genentech | IgE | Asthma | Serum | There was a large difference in reduction in exacerbations after 48 weeks with omalizumab treatment between the high and low periostin groups (30% vs. 3%) [172]. |
| Serum | Omalizumab significantly reduced serum periostin levels at 4 and 8 weeks after the start of the treatment [170]. | ||||
| Serum | Serum periostin levels decreased in omalizumab-treated patients in comparison to conventionally treated patients. This effect was remarkably apparent only if CRSwNP was not present [173]. | ||||
| Mepolizumab | GlaxoSmithKline | IL-5 | Asthma | Nasal secretion | Nasal periostin levels decreased significantly after 8 weeks of treatment with mepolizumab [172]. |
| Dupilumab | Regeneron/Sanofi | IL-4 Rα | Asthma | Serum | Peripheral blood eosinophil and FeNO concentrations were associated with lower exacerbation frequency and improved respiratory function, whereas periostin concentrations were associated only with improved respiratory function [60]. |
| AD | Serum | During dupilumab treatment, disease severity-related serum periostin significantly decreased [122]. | |||
| Tralokinumab | AstraZeneca | IL-13 | Asthma | Serum | FeNO (>32.3 ppb) and periostin (>27.4 ng/mL) were identified as the only biomarkers potentially predictive of treatment effect [167]. |
| IPF | Serum | Tralokinumab did not demonstrate a significant change in percent predicted FVC from baseline to Week 52 for either the periostin-high or the periostin-low group [174]. | |||
| Pirfenidone | Genentech | TGF-β1, TNF-α | IPF | Serum | Several baseline biomarkers (CCL13, CCL18, CXCL13, CXCL14, periostin, and YKL40) were prognostic for progression outcomes with pirfenidon treatment [175]. |
AD, Atopic dermatitis; IPF, Idiopathic pulmonary fibrosis; IL, interleukin; Rα, Receptor alpha; TGF-β, Transforming growth factor-beta; TNF-α, Tumour Necrosis Factor-α; FeNO, Fractional exhaled nitric oxide; FEV1, Forced Expiratory Volume in one second; CCL, C-C motif chemokine; CXCL, C-X-C motif chemokine; YKL-40, Anti-Chitinase-3-like protein 1.